Endometrial Carcinoma — Trials

Endometrial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 109
Recruiting: 52
Ph III recruiting: 4
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05827614	Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE)	terminated	Phase 1	85	Boundless Bio, Inc.INDUSTRY	1	Aug 19, 2026	clinicaltrials
NCT05714553	NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	terminated	Phase 1 / Phase 2	19	NuCana plcOTHER	1	Jul 23, 2026